Evidence map›Paper›PMID 31864396›Full record

ArticleSubstance abuse treatment, prevention, and policy2019

Peer involvement and cross-sector efforts in establishing integrated treatment of hepatitis C virus infection for people with substance use disorders: experiences from Norway.

Ole Jørgen Lygren, Ronny Bjørnestad, Else-Marie Løberg, Martine Lepsøy Bonnier, Vibeke Bråthen Buljovcic, Kjell Arne Johansson, Lars T Fadnes, INTRO-HCV Study Group

Open access · goldAbstract read
In one paragraph

Article in Substance abuse treatment, prevention, and policy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 79% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Ole Jørgen LygrenProLAR Nett, Søgne, Norway.
Ronny BjørnestadProLAR Nett, Søgne, Norway.
Else-Marie LøbergBergen Addiction Research Group, Department of Addiction Medicine, Haukeland University Hospital, Avdeling for rusmedisin, Postboks 1400, 5021, Bergen, Norway.
Martine Lepsøy BonnierAgency for mental health and substance abuse services, Bergen municipality, Norway.
Vibeke Bråthen BuljovcicBergen Addiction Research Group, Department of Addiction Medicine, Haukeland University Hospital, Avdeling for rusmedisin, Postboks 1400, 5021, Bergen, Norway.
Kjell Arne JohanssonBergen Addiction Research Group, Department of Addiction Medicine, Haukeland University Hospital, Avdeling for rusmedisin, Postboks 1400, 5021, Bergen, Norway.
Lars T FadnesBergen Addiction Research Group, Department of Addiction Medicine, Haukeland University Hospital, Avdeling for rusmedisin, Postboks 1400, 5021, Bergen, Norway. ars.fadnes@uib.no.ORCID 0000-0001-8757-2092
INTRO-HCV Study Group
Haukeland University Hospital · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFor people with opioid dependence in Norway, chronic hepatitis C virus (HCV) infections contribute to high mortality and high morbidity. Around 50% of patients in medically assisted rehabilitation (MAR) have been shown to have HCV, and the current prevention and control efforts have been mostly unsuccessful. Thus, there is a need for new strategies for people-centred service delivery and innovative methods to improve health outcomes.

methodsOver the last few years, the city of Bergen, Norway, has developed a cross-sector collaboration with substantial peer involvement in research and health provision related to substance use. User group representatives for people receiving MAR, addiction medicine health personnel, infectious disease specialists, policy makers in the municipality, low-threshold health care centres for people with substance use disorders in Bergen Municipality and researchers in the INTRO-HCV project have made concerted efforts in this regard. We will present here some of the strategies and steps we have taken.

resultsWe have established an integrated HCV treatment scheme for people who inject drugs or who have opioid dependence. More than 800 persons have been tested for HCV within these frames, and more than 250 persons have been given treatment for HCV within the project. The integrated treatment of HCV is offered both in MAR outpatient clinics, municipal low-threshold healthcare centres, and local and regional prisons. The preliminary results indicate an increase in HCV treatment uptake among those receiving integrated treatment (96% initiating treatment compared to 75%). The user group organisation ProLAR Nett has established an outreach service to screen for HCV, increase awareness and reduce the proportion of people unknowingly living with HCV while informing and motivating people to receive treatment. Together with the other stake holders, peer user group, health care, research planning, concert events, and policy panels have been held.

conclusionsPeer involvement seems to have increased testing rates for HCV and acknowledgment of its importance. This seems to have improved health care for people with opioid dependence in Bergen over the last few years, particularly relating to the treatment of HCV. These experiences might be helpful in the planning of integrated policies in other settings that seek to eliminate the HCV endemic.

Indexed as

Delivery of Health Care, IntegratedPeer GroupHepatitis CHumansNorwayOpioid-Related DisordersSubstance Abuse, IntravenousSubstance Abuse Treatment CentersChronic hepatitis CIntegrated health careOpiate substitution treatmentSubstance abuse treatment centers

Identifiers

PMID31864396
PMCPMC6925489
OpenAlexW2995157786

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.